Investing Across the Ecosystem: Breakthroughs are happening in many areas of drug development beyond traditional therapies.

Parsing Commercial Complexity: Strategy must shift from science to execution as products approach the market.

Growing Opportunity Set: Life science markets offer high-conviction, risk-adjusted return potential.

Long Term Orientation: We rely on patient capital that supports steady investment through volatility.

Biopharma innovations including targeted therapies, gene editing, and advanced protein therapeutics that transform patient outcomes.

Healthcare technology platforms enabling remote patient management, AI-powered diagnostics, and cloud-based automation solutions.

Medical devices and robotics focused on minimally invasive procedures, chronic disease management, and precision diagnostics.